PRMT5-mediated arginine methylation of FXR1 is essential for RNA binding in cancer cells
University of New Mexico Comprehensive Cancer Center
Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.
Melanoma, an aggressive form of skin cancer that accounts for 75% of all skin-cancer-related deaths, is often detected later in people with darker skin complexions — and the consequences can be devastating, a Mayo Clinic study reveals.
A UCLA-led study suggests women who are 65 years old or older with high-risk breast cancer and are treated with chemotherapy are more likely to develop a substantial decline in physical function.
ASCO, the largest event in cancer research, is approaching on May 31st. ASCO offers tailored scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.
Esophageal cancer (EC) is an aggressive malignancy with a poor prognosis, with its development and progression potentially influenced by changes in the esophageal microbiome. Recent studies have revealed that specific microbiome compositions might be linked to EC's development, response to treatment, and patient prognosis.
Blue light improves bladder cancer detection across races; Gamma waves distinguish goal-oriented movements; Giving abnormal bone formation a closer look; Dissecting the HIV-1 transcriptional circuitry
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.
A groundbreaking multicenter cohort study in China has illuminated the impact of sex on the outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC), the most common type of liver cancer.
A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and phosphatidylserine (PS) significantly enhances the ability of human natural killer (NK) cells to lyse hematologic malignancies (HMs).
Sylvester Comprehensive Cancer Center today announced establishment of the Sylvester Brain Tumor Institute. It will focus on personalized medicine approaches for treating all patients with brain tumors.
A new Lancet Oncology article describes how climate-driven risks in the Caribbean negatively affect every step in the cancer control continuum, from etiology to survivorship.
How a non-invasive technique temporarily opened the blood-brain barrier to deliver an immunotherapy drug to the brain in a large animal study.
Susan G. Komen commends the Georgia General Assembly and Governor Brian Kemp for allocating $796,000 in the FY2025 budget for the state's Breast and Cervical Cancer Program.
Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors—an advance that could transform cancer treatment. The promising findings, reported today in Science Advances, involve CAR-T cell therapy, which supercharges the immune system to identify and attack cancer cells.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Three nurses have been named recipients of Rutgers Cancer Institute’s ‘Oncology Nursing Excellence Awards’ during Nurses Week this year. This year’s award recipients were named during the annual Elizabeth Gibby Osborne Lecture.
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) have again received an internationally recognized accreditation for cellular therapy and stem cell transplantation from the Foundation for the Accreditation of Cellular Therapy (FACT), giving patients life-saving cancer treatment options in Connecticut.
Showing results
1–20 of 24770